GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Long-Term Debt & Capital Lease Obligation

Mega Genomics (HKSE:06667) Long-Term Debt & Capital Lease Obligation : HK$40.2 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Mega Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$40.2 Mil.

Warning Sign:

Mega Genomics Ltd has been issuing new debt. Over the past 3 years, it issued CNY 21.508 million of debt. But overall, its debt level is acceptable.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Mega Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$40.2 Mil. Mega Genomics's Total Assets for the quarter that ended in Jun. 2024 was HK$895.8 Mil. Mega Genomics's LT-Debt-to-Total-Asset for the quarter that ended in Jun. 2024 was 0.05.

Mega Genomics's LT-Debt-to-Total-Asset increased from Jun. 2023 (0.01) to Jun. 2024 (0.05). It may suggest that Mega Genomics is progressively becoming more dependent on debt to grow their business.


Mega Genomics Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Mega Genomics's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Long-Term Debt & Capital Lease Obligation Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt & Capital Lease Obligation
186.03 13.83 6.55 5.03 39.41

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only 8.70 5.03 6.28 39.41 40.23

Mega Genomics Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Mega Genomics  (HKSE:06667) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mega Genomics's LT-Debt-to-Total-Asset ratio for the quarter that ended in Jun. 2024 is calculated as:

LT-Debt-to-Total-Asset (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=40.23/895.757
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Mega Genomics Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics Business Description

Industry
Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
Executives
Dongyin Industrial (shenzhen) Co., Ltd. 2106 Person having a security interest in shares
Dongyin (tianjin) Enterprise Management Consulting Co., Ltd. 2106 Person having a security interest in shares
Dongfu Hetong (tianjin) Equity Investment Fund Partnership Enterprise (limited Partnership) 2106 Person having a security interest in shares
Yurong Technology Limited 2101 Beneficial owner
Dongfu (beijing) Investment Management Co., Ltd. 2106 Person having a security interest in shares
Dong Yin Development (holdings) Limited 2106 Person having a security interest in shares
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares
Beijing Dongfu Huitong Investment Management Center (limited Partnership) 2106 Person having a security interest in shares
Guo Meiling 2101 Beneficial owner
Yu Rong 2501 Other
Lin Lin 2101 Beneficial owner
Infinite Galaxy Health Limited 2101 Beneficial owner
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other

Mega Genomics Headlines

No Headlines